A promising infection fighter whose development was stalled by bankruptcy several years ago has regained momentum, thanks to Boston-based investors who carried the torch for a treatment that could cut the death rate among kidney dialysis patients.

Neutrolin, an anti-bacteria liquid, is back in development with the goal of preventing catheter infections during kidney dialysis. Biopharmaceutical company CorMedix Inc., which raised $12.5 million through an initial public offering in March, forecasts the treatment could hit the U.S. market by 2013.

“So many people die of infection,” said Frank Prosl, a Duxbury engineer who received the patent on Neutrolin. “There is no fundamental treatment in the market to correct this.”

Prosl helped found Mansfield-based BioLink Corp., which developed a way to prevent infection from invading the inside of catheters used for kidney dialysis. Previously, it was thought that the insertion of catheters introduced infection from the outside into the patient, Prosl said.

Paid Article @ Boston Business Journal